vicriviroc

A piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. Vicriviroc is designed to bind to CCR5 and inhibit… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2018
0102020052018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
HIV-1 develops resistance to CCR5 antagonists such as Maraviroc (MVC) and Vicriviroc (VVC) both in vitro and in vivo, with most… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2010
2010
BACKGROUND Agents that block the CCR5 coreceptor for human immunodeficiency virus (HIV) have demonstrated potent antiretroviral… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
High-throughput sequencing platforms provide an approach for detecting rare HIV-1 variants and documenting more fully… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
HIV-1 variants resistant to small molecule CCR5 inhibitors such as vicriviroc (VVC) have modified Env complexes that can use both… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study… (More)
  • table 1
  • figure 1
Is this relevant?
2008
2008
Little is known about the in vivo development of resistance to human immunodeficiency virus type 1 (HIV-1) CCR5 antagonists. We… (More)
Is this relevant?
2008
2008
Several small molecule drugs that bind to the host CCR5 co-receptor and prevent viral entry have been developed for the treatment… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study… (More)
Is this relevant?
2007
2007
OBJECTIVE To determine antiviral activity, pharmacokinetic properties, and safety of vicriviroc, an orally available CCR5… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inhibiting human immunodeficiency virus type 1 (HIV-1) infection by blocking the host cell coreceptors CCR5 and CXCR4 is an… (More)
Is this relevant?